Can edoxaban be used at extremes of bodyweight and in patients with a creatinine clearance ≥95 ml/min? - A population pharmacokinetic analysis.
Rachel E ClaphamVictoria SpeedRosalind ByrneLara N RobertsJulia CzuprynskaEmma GeeSinead DuffyRachna PatelRaj K PatelRoopen AryaJignesh P PatelPublished in: Thrombosis research (2024)
Our population PK model for edoxaban suggests that renal function is a key driver for overall edoxaban exposure. Further clinical outcome data is required to understand clinical effectiveness and adverse outcomes.